Xiamen Amoytop Biotech (688278) Stock Overview
Engages in research, development, production, and sale of recombinant protein drugs in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
688278 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Xiamen Amoytop Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥83.54 |
| 52 Week High | CN¥93.52 |
| 52 Week Low | CN¥66.00 |
| Beta | -0.23 |
| 1 Month Change | 9.40% |
| 3 Month Change | 0.66% |
| 1 Year Change | 22.05% |
| 3 Year Change | 113.55% |
| 5 Year Change | 138.75% |
| Change since IPO | 136.66% |
Recent News & Updates
Shareholder Returns
| 688278 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | 1.1% | -1.0% | 0.8% |
| 1Y | 22.0% | -0.07% | 16.5% |
Return vs Industry: 688278 exceeded the CN Biotechs industry which returned -0.1% over the past year.
Return vs Market: 688278 exceeded the CN Market which returned 16.5% over the past year.
Price Volatility
| 688278 volatility | |
|---|---|
| 688278 Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 4.0% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in CN Market | 9.0% |
| 10% least volatile stocks in CN Market | 3.0% |
Stable Share Price: 688278 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688278's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 2,685 | Li Sun | www.amoytop.com |
Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd.
Xiamen Amoytop Biotech Co., Ltd. Fundamentals Summary
| 688278 fundamental statistics | |
|---|---|
| Market cap | CN¥34.10b |
| Earnings (TTM) | CN¥939.58m |
| Revenue (TTM) | CN¥3.34b |
Is 688278 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688278 income statement (TTM) | |
|---|---|
| Revenue | CN¥3.34b |
| Cost of Revenue | CN¥239.07m |
| Gross Profit | CN¥3.10b |
| Other Expenses | CN¥2.16b |
| Earnings | CN¥939.58m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.30 |
| Gross Margin | 92.85% |
| Net Profit Margin | 28.11% |
| Debt/Equity Ratio | 3.8% |
How did 688278 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/10 23:03 |
| End of Day Share Price | 2025/12/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xiamen Amoytop Biotech Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Sophia Zhang | China Stock Investment Research Co. Ltd. (GZ500..com) |
| Shitong Han | Citic Securities Co., Ltd. |